Objectives: To establish the risk of subsequent intractable epilepsy after ≥2, ≥5, and ≥10 years of remission in childhood-onset epilepsy. Methods: From the Nova Scotia childhood-onset epilepsy population-based cohort patients with all types of epilepsy were selected with ≥20 years follow-up from seizure onset (incidence cases). Children with childhood absence epilepsy were excluded. The rate of subsequent intractable epilepsy was then studied for patients with ≥5 years remission on or off AED treatment and compared with the rate for those with ≥2 and ≥10 years of remission. Results: Three hundred eighty-eight eligible patients had ≥20 years follow-up (average 27.7 AE (standard deviation) 4 years) until they were an average of 34 AE 6.5 years of age. Overall, 297 (77%) had a period of ≥5 years of seizure freedom (average 21.2 AE 8 years), with 90% of these remissions continuing to the end of follow-up. Seizures recurred in 31 (10%) and were intractable in 7 (2%). For the 332 with a remission of ≥2 years seizure-free, 6.9% subsequently developed intractable epilepsy (p = 0.001). For the 260 with ≥10 years remission, 0.78% subsequently developed intractable epilepsy (p = 0.25 compared with ≥5 years remission). Significance: Even after ≥5 or ≥10 years of seizure freedom, childhood-onset epilepsy may reappear and be intractable. The risk is fortunately small, but for most patients it is not possible to guarantee a permanent remission.
Most children with epilepsy eventually outgrow their seizures. [1] [2] [3] [4] Unfortunately some will have a significant remission but later in life develop intractable epilepsy. Berg et al. 5 questioned 333 patients (nearly all adults) with intractable focal epilepsy who underwent resective surgery for their epilepsy at six specialized centers in the United States. Epilepsy onset was during childhood in 245 (74%), with 194 having an onset at <15 years of age. Overall, 8 .5% retrospectively reported a remission of at least 5 years before their surgical evaluation, with the longest remission being 28 years. Several prospective studies have indicated that the clinical course of childhood epilepsy may include periods of intractability and remission. [6] [7] [8] In the current study, we have used the Nova Scotia population-based childhood onset epilepsy cohort to prospectively answer the following question: How many children with epilepsy will have a remission of at least 5 years followed by intractable epilepsy during ≥20 years of follow-up? Although any recurrence after such a long remission is likely discouraging to patients, later intractable epilepsy could be devastating, with major effects on education, employment, social relationships, and mental health.
Methods
Patients were selected from the Nova Scotia populationbased study of childhood epilepsy with the following characteristics: follow up ≥20 years from the first seizure, any type of epilepsy except for childhood absence epilepsy and daily antiepileptic drug (AED) treatment beginning shortly after the diagnosis of epilepsy. The exclusion of absence epilepsy was the result of a different data collection scheme for these patients that did not include issues of remission and relapse over many years. In addition, the length of their follow-up from seizure onset did not extend beyond a mean of 14.1 AE (standard deviation) 3.5 years. 9 The Nova Scotia Childhood Epilepsy cohort consists of all children who developed epilepsy in this Canadian province between 1977 and 1985. Age at onset was between 1 month and 16 years and all patients had at least two unprovoked seizures. Patients with a progressive brain disorder such as a brain tumor or neurodegenerative disorder were excluded. The case finding method has been described previously and was based on the observation that all children presenting to the healthcare system in Nova Scotia with one or two seizures will have an electroencephalography (EEG) study. 10, 11 All EEG studies for children were interpreted in a single center. We reviewed all EEG requests for the study period, reviewed the medical charts, and contacted the patient and family directly to establish the diagnosis of new-onset epilepsy. We have personally contacted the patients and their families periodically over the last~30 years.
Intractable epilepsy was defined as ≥1 seizure every 2 months in the last year of follow-up despite treatment with three appropriate AEDs. This definition appears reliable and predates the more recent recommendations from the International League Against Epilepsy (ILAE). 12, 13 Six patients died after a follow up of ≥20 years (one from drowning during a seizure and five from causes not related to epilepsy). All six were included in the analysis, with their age at death defining the end of follow-up.
Statistical analysis used SPSS version 15.0 with chisquare and t-tests. We used the Wilson system for calculating 95% confidence intervals (CIs) for point estimates. 14, 15 Statistical significance was defined as p < 0.05.
This study was approved by the IWK Health Centre Research and Ethics Board.
Results
The total Nova Scotia cohort includes 692 patients with all types of epilepsy. For this study, 97 were excluded with epilepsies characterized primarily by absence seizures and 16 were excluded who were never treated with AEDs. Of the remaining 579 patients, we could obtain follow-up data for 554 patients (96%) of whom 388 (70%) had a follow-up of ≥20 years and were eligible for this study (Fig. 1) .
Demographic and other data are noted in Table 1 . Age at onset averaged 6.5 AE 4.5 years (range 1 month to 16 years). Average follow-up was 27.7 AE 4 years (range , and at the end of follow-up the average age was 34 AE 6.5 years (range 20.5-48). In Table 1 , patients with a ≥20-year follow-up and a remission of ≥5 years are compared with those with a similar follow-up without a ≥5-year remission. Not surprisingly, those without a ≥5-year remission were more likely to have concomitant intellectual disability and generalized non "idiopathic" epilepsies. They were much more likely to have intractable epilepsy at the end of follow-up (66% vs. 2%, p < 0.0001).
Of the patients with ≥20 years of follow-up, 297 (77%) had a remission of ≥5 years at some point during follow-up. The time from seizure onset to the beginning of the ≥5-year remission averaged 6 AE 7 years (median 4, range 0-31 years), although 98 (25%) of 388 had the onset of remission ≤1 year after seizure onset. Prior to the remission, the average number of AEDs was 1.9 AE 1.3 (median 4). The duration of these remissions averaged 21.2 AE 8 years (range 5-36.5 years), and in 90% the remissions continued until the end of follow-up ("terminal remission"). On
Key Points
• Over a ≥20-year follow-up of a population-based cohort of children with new-onset epilepsy, 86% had a remission of ≥2 years, 77% of ≥5 years, and 67% of ≥10 years
• Intractable epilepsy occurred after a ≥2-year remission in 6.9%, ≥5 year in 2%, and ≥10 year in 0.78%; the difference between ≥2 and ≥5 was significant (p = 0.001)
• The length of remission followed by intractable epilepsy for ≥5-year remission group ranged from 5 to 18.5 years average 5 AE 6.2 years of the remission occurred while the patient was receiving AED treatment and 16.7 AE 9.8 years without any AED treatment. A total of 255 (86%) discontinued AEDs during the period of ≥5-year remission, but 40 (14%), for various reasons, continued with daily medication despite the remission. Overall, 265 (90%) of 296 remained seizure-free after the ≥5-year remission until the end of follow-up and 45 (12%) of 388 had "smooth sailing epilepsy" (i.e., no further seizures once medication was started and continued to be seizure-free when AED treatment was discontinued 10 ).
For 31 of 296 (10-95% CI 7.5-14.4%) there were recurrent seizures after their remission of ≥5 years and in 7 of 296 (2-95% CI 1.1-4.8%) intractable epilepsy followed their ≥5-year remission and continued until the end of follow-up. These seven patients with intractable epilepsy had "symptomatic generalized epilepsy" (n = 1), focal epilepsy (n = 5), and unclassified epilepsy. 1 The causes of their epilepsies were the following: cortical malformation (n = 1), perinatal encephalopathy (n = 2), posttraumatic encephalopathy (n = 1), and unknown (n = 3). The duration of their remissions were 5 years (n = 4), 7.5 years (n = 1), 12 years (n = 1), and 18.5 years (n = 1). By the end of their ≥5-year remissions, three patients had not discontinued AED treatment; however, four had discontinued medication and had substantial periods without seizures and without AED treatment before becoming intractable (3, 5, 8, and 16 years). The patients with 8 and 16 years who were seizure-free off AED treatment met the suggested criteria for "permanent remission" with >10 years seizure-free and ≥5 of these years without AED treatment. 16 For the overall cohort of 388 with a ≥20-year follow-up, 22 (6%) underwent epilepsy surgery. None of these patients had a ≥5-year remission prior to surgery, although 11 had such a remission after surgery.
Patient inclusion was changed to consider the effect of a shorter and longer remission on the risk of later intractable epilepsy (Table 2 ). There were 332 patients (86%) patients with a ≥2-year remission, and within this group 56 (17%) had further seizures of whom 23 (6.9-95% CI 4.6-10.2%) were considered intractable at the end of follow-up (p = 0.01, relative risk 1.48: 95% CI 1.2-1.83 for comparison of intractability after ≥2 year vs. ≥5-year remission). There were 260 patients (67%) with a ≥10-year remission and within this group 15 (6%) had further seizures of whom two (0.78-95% CI 0.2-2.8%) were intractable at the end of follow-up after remissions of 12 and 18 years. One had focal epilepsy and one unclassified epilepsy. The comparison of the proportion with intractability after ≥10 years versus after ≥5-year remission was not statistically significant (p = 0.25).
Discussion
Population-based studies indicate that a large proportion of children with epilepsy "outgrow" their seizures; however, it is also clear that many have a relapsing remitting course. 6, 7, [17] [18] [19] Even intractable epilepsy in childhood frequently remits during lengthy follow-up. 8, 18, 19 Our study emphasizes the opposite-after a substantial remission (≥5 years) from childhood epilepsy, intractable seizures may develop during a follow-up of ≥20 years. The risk of intractable epilepsy after a ≥5-year remission is small (~2%) and may be even lower after ≥10 years of remission (~1%), although the difference was not statistically significant. After a ≥2-year remission, the risk of intractable epilepsy was significantly higher (~7%); therefore, a remission of ≥5 years is more reassuring. Clearly, it is not possible to guarantee that seizure freedom will persist even after a long remission, and if seizures recur they may be intractable to medical therapy. The only epilepsy syndrome that has a virtual 100% remission rate by late adolescence is rolandic epilepsy. 20 Previous studies have not addressed the issue of later intractable epilepsy after prolonged remission; however, two population-based cohorts have examined the risk of recurring seizures after prolonged remission. The Connecticut study includes 613 children with epilepsy recruited from neurology offices. Five hundred sixteen were followed for ≥10 years, of whom 328 (63%) had a "complete remission" defined as ≥5 years seizure-free without AED treatment. 21 After a complete remission, 23 (7%) of 328 relapsed. There were 138 who had >10 years of follow-up after achieving "complete remission," and none of these patients recurred. A recent publication about the long follow-up experience of Professor Sillanpaa in Turku Finland (44 years, median) observed that in a smaller cohort of incidence childhood epilepsy cases (n = 148), after 5 years of remission on or off AEDs,~40% later relapsed, and after 10 years of remission on or off AED treatment,~20% later relapsed. 22 "Relapsed" meant further seizures but the risk of intractable epilepsy was not reported. The magnitude of these relapse rates is startling but the Finland study differs from other population-based cohorts. For example, in Finland, a higher proportion of patients had "primary generalized epilepsy" (55%) compared with the current Nova Scotia cohort (16%), and fewer had focal epilepsy (43%) compared with 62% in Nova Scotia. In the population-based study of childhood-onset epilepsy from Olmstead county, Minnesota (n = 359), 68% had focal epilepsy, and in the Connecticut epidemiologic study (n = 691), 59% had focal epilepsy. 23, 24 In addition, the relapse rate in our present study after a ≥5-year remission was only 10% and after ≥10 years it was 6%, which is also similar to the Connecticut study. 21 It is unclear why the Finland cohort differs. In a separate publication about the Finland cohort, of 144 patients with new-onset epilepsy and a follow-up of 30 years, 20 patients (14%) had a ≥5-year remission followed by persistent epilepsy to the end of follow-up. 25 It is not stated exactly how frequent the seizures were or how intensive the medical treatment was; however, none of these patients underwent epilepsy surgery. Again, this very high rate of unsatisfactory long-term outcome is startling.
Our study has limitations. Even though the sample size is substantial and follow-up was long (27.7 AE 4 years), the absolute number of patients with intractable epilepsy after ≥5 years of remission (n = 7) is too small to develop We cannot comment on why this treatment had not been pursued. Based on the small numbers it is not possible to reliably estimate if intractability after remission is more likely after focal versus generalized epilepsy. Five of the seven had focal epilepsy of a total of 185 patients with focal epilepsy other than rolandic. None of the 72 with "idiopathic generalized epilepsy" had intractability after remission, suggesting that the problem of late intractability after remission is seen mostly in focal epilepsy. It is also possible that current medical treatments for epilepsy have a greater effect on long-term remission than those that were available to our cohort at the time of diagnosis; however, there are no data to support or refute this idea. Many experts suggest that newer medications are better tolerated, but probably not more effective than the traditional AEDs used our cohort. [26] [27] [28] [29] Decisions about discontinuing AED treatment in our cohort were made clinically and not subject to a standard protocol. Finally, we were not able to quantify exactly when intractable epilepsy began after a prolonged remission. We only know that the patient's epilepsy was medication resistant for the final year of follow-up, although for most intractable seizures were underway for many years.
The reasons that some patients have a very long remission and then develop intractable epilepsy are mysterious. Poor medication adherence is unlikely, especially because four of the seven had been without AED treatment for 3-16 years. It is unclear if a particular cause or specific localization has a propensity for this unfortunate outcome. Our results suggest that children with epilepsy are likely to have a "permanent" remission once they have been seizure-free for ≥5 or ≥10 years, but families should be cautioned that there is a very small risk that their epilepsy will return and be difficult to treat. It appears nearly impossible to guarantee a permanent remission.
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